Mydecine Innovations Group Inc.

05/24/2022

At Mydecine, we have a global team with hundreds of years of experience in medicinal chemistry, pharmaceutical drug development, and regulatory and IP strategy from top pharmaceutical and research institutions.

Through our exclusive partnership with Applied Pharmaceutical Innovation, working out of the University of Alberta, we have an end-to-end drug development infrastructure under one roof that allows Mydecine to retain 100% IP ownership.

We have a growing library of novel molecules tailored specifically for medical use. Using a modular patent strategy allows us to mix and match different feature sets to maximize portfolio protection and value.

We are rapidly preparing to submit our IND application for the first and only industry-sponsored trial assessing psilocybin for . Johns Hopkins University is the lead investigator for the study.

To learn more about our clinical trial and drug development efforts visit our website:

Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology company developing innovative first- and second-generation novel compounds for the treatment of mental health and addiction through world-class technology and drug development infrastructure. The company's world-reno...

05/02/2022

At Mydecine, we are developing improved second-generation psychedelic molecules for medical use. While there is a growing body of evidence to support the safety and efficacy of molecules like naturally occurring psilocybin, we believe that in order to make these treatments accessible to all, we need to improve upon these first-generation compounds.

MYCO-004 is an excellent example of how we are tailoring psilocybin for medical use as well as strengthening our IP portfolio.

MYCO-004 is a short-acting, skin-permeable, patch-delivered tryptamine compound that has a faster onset time with reduced side effects compared to classic psilocybin. Each of these feature sets carries its own layer of patent protection.

Watch the full video to learn more about our drug development program: https://bit.ly/3hGBDWy

​​$MYCO.NE $MYCOF $ONFA.F

Invest in the future of mental health today!Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Mydecine Investor Deck: https://www.mydecine...

04/11/2022

Great read touching on the behind-the-scenes aspects of funding psychedelic research and Dr. Matthew Johnson's groundbreaking work in this field!

Partnerships between funders and researchers at Johns Hopkins illustrate how companies influence the direction of psychedelic science and the release of research data to the public domain.

04/09/2022

Chief Medical Officer Dr. Rakesh Jetly, shared his opinion with Psychedelics Today on available mental health treatments and the need for new ones.

"We’ve seen modest improvement in mental health care over the years. However, I firmly believe we need to do better in this arena. Far superior advances have been made in the treatment of cancer, heart disease, and many other conditions that take an enormous toll on society and represent a significant medical and economic burden.

Yet in the field of mental health, so many patients continue to suffer without adequate or effective treatment. We must review the data while being mindful that each file or data point represents a person who is struggling. We must work to develop medicines with better results, realizing that mental health disorders affect not only patients, but their families and loved ones, their careers and communities."

Read the full story:https://bit.ly/3JreaEg

04/07/2022

Today we celebrate World Health Day and reiterate our commitment to promoting health and well-being by creating new therapies for patients – particularly in areas of unmet need in the medical community.

World Health Day presents the perfect opportunity to thank those who share Mydecine’s vision. We’re grateful for the investors, research partners, global medical centers and healthcare providers who are working to bring new therapies with meaningful results to people in need around the world.

Let’s keep pushing forward to remove stigmas around mental health, identify areas of evolving need and create safe, evidence-based medicines. Working together, we can change lives.



www.mydecine.com

03/31/2022

In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (WHO) brief released earlier this month (https://bit.ly/378Lwu8). WHO also pointed out young people and women have been more severely impacted by the pandemic than men.

Additionally, the Federal Trade Commission reported that after decades of declining cigarette sales, 2020 marked the first time in 20 years cigarette sales actually increased in the United States.

The global COVID-19 pandemic forced millions of people to work from home making it easier than ever to take a smoke break. Pair that with the added stress of uncertainty and concerns for the health of loved ones, cigarette sales increased by $8.4 Million dollars in 2020.

Mydecine was founded to address these growing concerns and the lack of innovative treatments for mental health and addictions disorders. Our global team is dedicated to efficiently developing new therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders.

The Mydecine business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy, as well as other novel, non-psychedelic molecules with therapeutic potential.

By collaborating with some of the world’s foremost authorities, Mydecine aims to responsibly fast-track the development of new medicines to provide patients suffering from mental health disorders with safe and more effective treatment options.

Learn more by visiting our website: https://www.mydecine.com/our-approach/ip-drug-development

In the first year of the COVID-19 pandemic, global prevalence of anxiety and depression increased by a massive 25%, according to a scientific brief released by the World Health Organization (WHO) today.

03/18/2022

What's the difference between first and second-generation novel therapeutics?

At Mydecine, we define a first-generation as a naturally occurring compound like or a known compound that has been previously studied like **A. Although the research showing the efficacy of these drugs is extremely encouraging, we believe these compounds need to be modified at the molecular level to be widely accepted and adopted by the general medical community.

Our NCE (new chemical entity) program is focused on improving these first-generation molecules to make second-generation drugs tailored for medical use. This portfolio of new drugs represents major improvements to existing natural and synthetics products, such as enhanced safety, efficacy, stability, dosing and reduced side effects.

Learn more by listening to CEO Josh Bartch's recent interview with Stock Box Media: https://bit.ly/3tkiwIs

$MYCO.NE $MYCOF

03/17/2022

In ten days and M-Vest are hosting the 2022 Virtual Growth Conference! Register by clicking the link below and watch CEO Josh Bartch's presentation available March 28-30th.

https://bit.ly/3MXStyu

$MYCO.NE $MYCOF $ONFA.F

03/17/2022

The Federal Trade Commission reported that after decades of declining cigarette sales, 2020 marked the first time in 20 years cigarette sales actually increased in the United States.

The global COVID-19 pandemic forced millions of people to work from home making it easier than ever to take a smoke break. Pair that with the added stress of uncertainty and concerns for the health of loved ones, cigarette sales increased by $8.4 Million dollars in 2020.

Safer more effective smoking cessation treatments are needed now more than ever. As we prepare for our upcoming phase 2b clinical trial, we are optimistic about the potential of psychedelic medicine to help people quit smoking.

Learn more about our clinical trial programs by visiting our website.
https://www.mydecine.com/our-approach/clinical-trials

$MYCO.NE $MYCOF $ONFA.F

03/08/2022

Mydecine has made strides towards our goals over the last few months! We continue to gain momentum as we reach significant milestones in our clinical trial programs and advance our drug development pipeline. Read our March company update here: https://bit.ly/3HW1KmJ

03/06/2022

We will be launching a phase 2b clinical trial in partnership with Johns Hopkins University led by Dr. Matthew Johnson. Dr. Johnson is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction and risk behavior. The planned study evaluates the administration of MYCO-001 with a structured smoking cessation treatment program in ni****ne dependent individuals.

Learn more about our study design in our blog post, "Can psilocybin help you quit smoking?" https://bit.ly/3sJAovK